<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BABS_UNSW_Australia_project_biosafety skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BABS UNSW Australia/project/biosafety</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container-fluid"><DIV class="navbar-header"><BUTTON type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false" aria-controls="navbar"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON></DIV><DIV id="navbar" class="navbar-collapse collapse"><UL class="nav navbar-nav navbar-right"><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia">Home</A></LI><LI class="dropdown"><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/project" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Project</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/overview">Vision</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/endosymbionts">Endosymbionts</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/project/phlow">pHlow system</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/pseudoknots">Pseudoknots</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/project/containment">Containment</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/project/futureapps">Applications</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/project/futurework">Future Work</A></LI></UL><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Practices">Human Practices</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Practices/Biosafety">Biosafety</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Team">Team</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Parts">Parts</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Attributions">Attributions</A></LI><LI class="dropdown"><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Notebook2" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Notebook</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Notebook2">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:BABS_UNSW_Australia/Protocols">Protocols</A></LI></DIV></DIV></DIV><NAV class="col-xs-3 bs-docs-sidebar"><UL id="sidebar" class="nav nav-stacked"><LI><A href="#Introduction">Introduction</A></LI><LI><A href="#Final">Final Safety Form</A></LI><LI><A href="#Chassis">Chassis Organisms</A></LI><LI><A href="#Elimination">Elimination</A></LI><LI><A href="#Substitution">Substitution</A></LI><LI><A href="#Engineering">Engineering Controls</A></LI><LI><A href="#Admin">Administrative Controls</A></LI><LI><A href="#PPE">Personal Protective Equipment</A></LI></UL></NAV><DIV class="col-xs-9"><P><STRONG>Introduction</STRONG></P><P>
Biosafety has been one of the major paradigms of project endosynbio. Our use of virulence factors and RG2 organisms, as well as the pathogenic nature of our engineered bacteria and the fact that this is our university’s first time at iGEM, has meant our intrinsic project design, protocol design and wet lab have been managed with extra regard for safety. See below for our final Safety Forms. 
</P><P id="Final">
Something which has struck our team on this journey, however, has been the lack of regulation and guidelines, especially in Australia, regarding unforeseen consequences in synthetic biology. We believe a shift in the philosophy of bacterial genetic engineering could really help to improve this and as such, have explored this as a human practices endeavour. Please see our detailed report, “Transforming biosafety: a new philosophy in synthetic biology.” 
</P><P><STRONG>Final safety form</STRONG></P><P><EM>New parts</EM></P><TABLE border="1" cellspacing="0" cellpadding="0" width="100%"><TBODY><TR><TD width="11%" valign="top"><P><STRONG>Part category</STRONG></P></TD><TD width="12%" valign="top"><P><STRONG>Species</STRONG></P></TD><TD width="5%" valign="top"><P><STRONG>Risk Group</STRONG></P></TD><TD width="10%" valign="top"><P><STRONG>Risk Group Source</STRONG></P></TD><TD width="9%" valign="top"><P><STRONG>Disease risk to humans</STRONG></P><P><STRONG>Y/N</STRONG></P></TD><TD width="10%" valign="top"><P><STRONG>Part number and name</STRONG></P></TD><TD width="16%" valign="top"><P><STRONG>Natural function of part</STRONG></P></TD><TD width="10%" valign="top"><P><STRONG>How was this part acquired?</STRONG></P></TD><TD width="14%" valign="top"><P><STRONG>How will you use it?</STRONG></P></TD></TR><TR><TD width="11%" rowspan="2" valign="top"><P>
                    pH promoters
                </P></TD><TD width="12%" valign="top"><P>
                    Escherichia coli K12
                </P></TD><TD width="5%" valign="top"><P>
                    1
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    Acid shock response promoter
                </P></TD><TD width="16%" valign="top"><P>
                    Promotes the transcription of genes involved in the acid shock response
                </P></TD><TD width="10%" valign="top"><P>
                    Synthesised in gBLOCK by IDT
                </P></TD><TD width="14%" valign="top"><P>
                    To promote the expression of listeriolysin O in the acidic endosome
                </P></TD></TR><TR><TD width="12%" valign="top"><P>
                    Lactococcus lactis subsp. lactis
                </P></TD><TD width="5%" valign="top"><P>
                    1
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    P170 pH promoter
                </P></TD><TD width="16%" valign="top"><P>
                    Involved in transcription of the <EM>cad </EM>operon
                </P></TD><TD width="10%" valign="top"><P>
                    Synthesised in gBLOCK by IDT
                </P></TD><TD width="14%" valign="top"><P>
                    To promote the expression of listeriolysin O in the acidic endosome
                </P></TD></TR><TR><TD width="11%" rowspan="2" valign="top"><P>
                    Invasion
                </P></TD><TD width="12%" valign="top"><P>
                    Listeria monocytogenes
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" valign="top"><P>
                    Y
                </P><P>
                    Listeriosis
                </P></TD><TD width="10%" valign="top"><P>
                    Listeriolysin O
                </P></TD><TD width="16%" valign="top"><P>
                    Virulence factor which permeabilises and ruptures the phagosomal membrane
                </P></TD><TD width="10%" rowspan="2" valign="top"><P>
                    Registry of Standard Parts
                </P><P>
                    Synthesised in gBLOCK by IDT
                </P></TD><TD width="14%" valign="top"><P>
                    To allow bacteria to enter the mammalian cell cytoplasm
         </P></TD></TR><TR><TD width="12%" valign="top"><P>
                    Yersinia pseudotuberculosis
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" valign="top"><P>
                    Y
                </P><P>
                    Acute enteric disease
                </P></TD><TD width="10%" valign="top"><P>
                    Invasin
                </P></TD><TD width="16%" valign="top"><P>
                    Binds to beta-1 integrins on mammalial cell surfaces to induce endocytosis
                </P></TD><TD width="14%" valign="top"><P>
                    To induce endocytosis of bacteria
                </P></TD></TR><TR><TD width="11%" rowspan="4" valign="top"><P>
                    Pseudoknots
                </P></TD><TD width="12%" valign="top"><P>
                    Murine mammary tumour virus
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    American Biological Safety Association
                </P></TD><TD width="9%" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    MMTV pseudoknot
                </P></TD><TD width="16%" rowspan="4" valign="top"><P>
                    Diverse roles including frameshift device
                </P></TD><TD width="10%" rowspan="4" valign="top"><P>
                    Synthesised in gBLOCK by IDT
                </P></TD><TD width="14%" rowspan="4" valign="top"><P>
                    To delay transcription of downstream genes by a quantified time value
                </P></TD></TR><TR><TD width="12%" valign="top"><P>
                    Avian infectious bronchitis virus
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    American Biological Safety Association
                </P></TD><TD width="9%" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    IBV pseudoknot
                </P></TD></TR><TR><TD width="12%" valign="top"><P>
                    Human coronavirus 229E
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" valign="top"><P>
                    Y
                </P><P>
                    Flu-like illness
                </P></TD><TD width="10%" valign="top"><P>
                    HCoV 229E pseudoknot
                </P></TD></TR><TR><TD width="12%" valign="top"><P>
                    Porcine transmissable gastroenteritis virus
                </P></TD><TD width="5%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    American Biological Safety Association
                </P></TD><TD width="9%" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    TGV pseudoknot
                </P></TD></TR><TR><TD width="11%" rowspan="4" valign="top"><P>
                    Toxin safety switch
                </P></TD><TD width="12%" rowspan="2" valign="top"><P>
                    Pseudomonas aeruginosa
                </P></TD><TD width="5%" rowspan="2" valign="top"><P>
                    2
                </P></TD><TD width="10%" rowspan="2" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="9%" rowspan="2" valign="top"><P>
                    Y
                </P><P>
                    Nosocomial infections including pneumonia
                </P></TD><TD width="10%" valign="top"><P id="Chassis">
                    Tse2 toxin
                </P></TD><TD width="16%" valign="top"><P>
                    Toxin
                </P></TD><TD width="10%" rowspan="4" valign="top"><P>
                    Registry of Standard Parts
                </P></TD><TD width="14%" valign="top"><P>
                    To kill cells when they do not simultaneously possess the sister plasmid, carrying the anti-toxin
                </P></TD></TR><TR><TD width="10%" valign="top"><P>
                    Tsi2 anti-toxin
                </P></TD><TD width="16%" valign="top"><P>
                    Specific self-protection mechanism
                </P></TD><TD width="14%" valign="top"><P>
                    To protect cells from the toxin
                </P></TD></TR><TR><TD width="12%" rowspan="2" valign="top"><P>
                    P1 bacteriophage
                </P></TD><TD width="5%" rowspan="2" valign="top"><P>
                    N/A
                </P></TD><TD width="10%" rowspan="2" valign="top"><P>
                    N/A
                </P></TD><TD width="9%" rowspan="2" valign="top"><P>
                    N
                </P></TD><TD width="10%" valign="top"><P>
                    Cre recombinase
                </P></TD><TD width="16%" valign="top"><P>
                    Site-specific recombination
                </P></TD><TD width="14%" rowspan="2" valign="top"><P>
                    To excise invasin and listeriolysin once cytoplasmic invasion is achieved
                </P></TD></TR><TR><TD width="10%" valign="top"><P>
                    Lox sites
                </P></TD><TD width="16%" valign="top"><P>
                    Site-specific recombination
                </P></TD></TR></TBODY></TABLE><P><EM>What is your chassis organism? Do you plan to experiment with any other organisms, besides your chassis?</EM></P><TABLE border="1" cellspacing="0" cellpadding="0" width="100%"><TBODY><TR><TD width="20%" valign="top"><P><STRONG>Species name </STRONG></P></TD><TD width="6%" valign="top"><P><STRONG>Risk Group</STRONG></P></TD><TD width="10%" valign="top"><P><STRONG>Risk Group Source</STRONG></P></TD><TD width="18%" valign="top"><P><STRONG>Disease risk to humans</STRONG></P><P><STRONG>Y/N</STRONG></P></TD><TD width="31%" valign="top"><P><STRONG>How was this organism acquired?</STRONG></P></TD><TD width="13%" valign="top"><P><STRONG>How will you use it?</STRONG></P></TD></TR><TR><TD width="20%" valign="top"><P>
                    Lactococcus lactis subsp. lactis
                </P></TD><TD width="6%" valign="top"><P>
                    1
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW (Jani O’Rourke lab)
                </P></TD><TD width="13%" rowspan="3" valign="top"><P>
                    These are our chassis organisms, or symbionts.
                </P></TD></TR><TR><TD width="20%" valign="top"><P>
                    Escherichia coli K12 Dh5-alpha
                </P></TD><TD width="6%" valign="top"><P>
                    1
                </P></TD><TD width="10%" valign="top"><P>
                    Canada PSDS
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW (Marc Wilkins lab)
                </P></TD></TR><TR><TD width="20%" valign="top"><P>
                    Synechocystis PCC6803
                </P></TD><TD width="6%" valign="top"><P>
                    1
                </P></TD><TD width="10%" valign="top"><P>
                    NIH
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW (Brett Neilan lab) and Macquarie University (Rob Lowe lab)
                </P></TD></TR><TR><TD width="20%" valign="top"><P>
                    HeLa cells*
                </P></TD><TD width="6%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    NIH
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW</P></TD><TD width="13%" rowspan="3" valign="top"><P>
                    These are our host cells for infection with symbionts.
                </P></TD></TR><TR><TD width="20%" valign="top"><P>
                    BHK-21 cells
                </P></TD><TD width="6%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    NIH
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW
                </P></TD></TR><TR><TD width="20%" valign="top"><P>
                    CHO-7 cells
                </P></TD><TD width="6%" valign="top"><P>
                    2
                </P></TD><TD width="10%" valign="top"><P>
                    NIH
                </P></TD><TD width="18%" valign="top"><P>
                    N
                </P></TD><TD width="31%" valign="top"><P>
                    Internal source at UNSW (Andrew Brown lab)
                </P></TD></TR></TBODY></TABLE><P>
    * Carries lysogenic HPV DNA within genome, however believed to pose no risk to humans
</P><P><EM>How will your project work?</EM></P><P>
    Our modified bacteria will be able to invade mammalian host cells using an IPTG and low pH driven invasin/listeriolysin O system (and in future work,
    hopefully be maintained at a stable population using AHL signalling systems). Our plasmid design ensures the invasive genes are de-activated once this
    invasion has occurred successfully, using delayed-timer pseudoknots and Cre recombination. A safety-switch system, maintained on two plasmids and
    integrated with the invasion system, will ensure no bacteria which leave the lab remain invasive and prevents horizontal gene transfer. This system is
    designed to pave the way for stable 'synthetic organelles' to be developed, with a medical application in mind.
</P><P><EM>What risks does your project pose at the laboratory stage? What actions are you taking to reduce those risks?</EM></P><P>
    Our project raises significant biosafety risks, as we are essentially generating novel pathogenic bacterial strains. In recognition of this, we assessed
    and managed our project laboratory risks using the Hierarchy of Hazard Control. The Hierarchy consists of five methods for hazard reduction beginning with
    the most effective, elimination, to the least effective, personal protective equipment. By using this system, risks can be managed appropriately. Some key
    examples of our risk management actions are illustrated below, as they were dealt with:
</P><P id="Elimination"><STRONG>ELIMINATION</STRONG></P><P>
    Many of our parts come from RG2 organisms, some of which are human pathogens. Instead of directly handling these organisms, we chose to order parts to be
    shipped from the Registry of Standard Parts or to be synthesised in the form of gBLOCKs from IDT. Thus this potential hazard was eliminated.
</P><P id="Substitution"><STRONG>SUBSTITUTION</STRONG></P><P>
    When ordered from the registry, we received an agar stab wherein invasin and lysteriolysin O were being constitutively expressed. This was extremely
concerning to our team. Thus, the constitutive promoter was removed and replaced in all of our invasive constructs by the inducible IPTG promoter.    </P><P id="Engineering"><STRONG>ENGINEERING CONTROLS</STRONG></P><P>
    Within a PC1 lab, a Class II biosafety cabinet was used for all bacterial work both to protect our work from contamination and to protect ourselves, and
    other laboratory users, from the invasive bacteria. A timer was installed near the cabinet to ensure UV decontamination occurred for at least 20 minutes
    following a wipe-down with 70% ethanol. Periodically, the efficacy of the hood was checked by resting an uncovered nutrient agar plate inside the cabinet,
    before incubation overnight at 37 degrees.
</P><P>
    All mammalian cell culture work occurred in a PC1 lab within a tissue culture hood.
</P><P id="Admin"><STRONG>ADMINISTRATIVE CONTROLS</STRONG></P><P>
    All team members completed Workplace Health and Safety, Ergonomics, Laboratory Safety and Green (environmental awareness) Laboratory courses to update
    basic safety knowledge. We were inducted into all laboratories and common equipment rooms. All reagents were labelled appropriately as either HAZARDOUS or
    NON-HAZARDOUS and briefed with safety information, the date and the owner. A computer was established within the laboratory with access to a copy of the
    laboratory safety manual, chemical inventory lists, biological inventory lists, safe working practices (SWPs) and risk assessments. Materials safety data
    sheets were also directly accessible.
</P><P>
    We are also researching and composing a report into the efficacy of current biosafety regulations, given the rapidly changing field and the lack of
    philosophical discussion regarding what it means to create a novel, persisting strain of bacteria. This work meant our team was in a safe, positive
    headspace regarding project decisions.
</P><P id="PPE"><STRONG>PERSONAL PROTECTIVE EQUIPMENT</STRONG></P><P>
    Gloves and laboratory gowns were worn by all team members when in the lab.
</P><P><EM>How would your project be used in the real world?</EM></P><P>
    Our project is in the first instance foundational. Much more research is required to optimise and ensure the safety and durability of this system. However,
    our long-term vision is to see these synthetic organelles be used in the human body. With the rise of organogenesis, this may be possible in the near
    future. </P><P><EM>
        What risks would your project pose, if it were fully developed into a real product that real people could use? What future work might you do to reduce
        those risks?
    </EM></P><P>
    The main risk would be the organisms becoming uncontrolled and invading non-target cells. Future work would require adding invasion specificity and
    extensive testing of how well the toxin/anti-toxin system functions. Another risk could be horizontal gene transfer of the toxin plasmid, causing damage to
    normal cells. We recognise that this kind of technology would be very difficult to trial <EM>in vivo</EM>.
</P></DIV></DIV></DIV></DIV></BODY></HTML>